- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Russell 3,000 Stocks Up More than 200% Year to Date
-
Russell Indexing Reshuffle Moves Healthcare Stocks: CXM, CTIC, HEB, CPD
-
A Healthy Dose of Funding for Pharma, Biotech
-
Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer
-
Best Performing Stocks of the Last Quarter
-
Dendreon: Charting the Course to Big Profits
-
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
-
Biotech Stocks and the ASCO-Effect
-
Russell 3000 Stocks Up 200% or More Year to Date
-
Access Pharma: A Smallcap Cancer Biotech Call Option Trade
-
A Biotech Triple Play: Dendreon, BioCryst and Arena
-
Why Sales Estimates for Dendreon's Provenge Are Too Low
-
Where the Big Money Is Betting Big
-
Why Did Dendreon Execs Cash Out on Friday?
-
Dendreon Investors Learn a Hard Lesson in Stop-Loss Orders
-
Dendreon: Bear Trap of the Year
-
Dendreon's Provenge Is Scientifically Intriguing but Commercially Nonsensical
-
Dendreon: At Times Wall Street Resembles a Casino
-
Dendreon: What Happened on April 28th?
-
Wednesday Closing Update
-
Wednesday's Options Recap
-
Fast Money Recap - Is This Apple Rumor True? (4/28/09)
-
Wall Street Breakfast: Must-Know News
-
FDA, Clinical Trial Updates: Watson Pharma, United Therapeutics, Auxilium, Dendreon
-
A Chance to Get Back in the Market
-
Best and Worst Performing Russell 3,000 Stocks Year to Date
-
Is Dendreon a $360 Stock - Or Is That Too Low?
-
FDA, Clinical Trial Calendar Updates: Actelion, Merck Discontinue Partnership
-
How Much Is Dendreon Worth?
-
How Dendreon Is Proving Short Sellers Wrong
-
Biotech Analyst Eats Dendreon's Provenge Crow
-
Dendreon: Short Squeeze Time
-
Updated FDA, Clinical Trial Calendars: Dendreon Releases Results
-
Wall Street Breakfast: Must-Know News
-
Dendreon Troubles Beyond Provenge Test
-
Tuesday's Options Recap
-
Dendreon's Positive IMPACT
-
Dendreon Holders: Protect Yourself
-
Dendreon: The Best Revenge
-
FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
-
Weekly Street Sentiment: Pause in the Bear-Bull Battle